

# NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

## HEALTH TECHNOLOGY APPRAISAL PROGRAMME

### Equality impact assessment – Scoping

#### STA Anakinra for treating Still's disease

The impact on equality has been assessed during this appraisal according to the principles of the NICE equality scheme.

1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they?

A consultee noted that in systemic onset juvenile arthritis anakinra is licensed and approved via NHS England clinical commissioning policy for treatment where macrophage activation syndrome is present. If similar provision is not made in adult onset Still's disease there is inequality between the treatment of children and adults with the same condition given that SJIA and AOSD are considered to be the same disease.

2. What is the preliminary view as to what extent these potential equality issues need addressing by the committee?

The appraisal will consider the population with Still's disease as a whole, and therefore any recommendations will cover both children with systemic Juvenile Idiopathic Arthritis and adults with adult-onset Still's disease, given that these are considered to be the same disease.

3. Has any change to the draft scope been agreed to highlight potential equality issues?

The scope has been amended to included reference to the group of patients with macrophage activation syndrome.

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the matrix been made?
No.

**Approved by Associate Director (name):** ...Frances Sutcliffe.....

**Date:** 06 March 2019